GlassScriptPhysician profile
Carlos Anias
NPI 1912725144
$4,006.39
in general payments reported to CMS, 2019-2025
18 companies · $4,006 in 2025
The $4,006 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $4,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,003 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.60 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $515.01 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $480.16 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $369.04 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $333.37 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $296.62 | 2025 | Austedo Xr, Uzedy |
| Alkermes, INC. | $286.40 | 2025 | Aristada, Lybalvi |
| Abbvie INC. | $264.77 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $258.96 | 2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $236.33 | 2025 | Invega Sustenna, Spravato |
| Indivior INC. | $224.17 | 2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $221.85 | 2025 | Hetlioz, Fanapt |
| Bausch Health US, LLC | $138.43 | 2025 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $122.34 | 2025 | Cobenfy |
| Braeburn INC. | $97.72 | 2025 | Brixadi |
| Collegium Pharmaceutical, INC. | $44.75 | 2025 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $43.17 | 2025 | Loreev Xr |
| Lundbeck LLC | $39.37 | 2025 | Rexulti |
| Luye Pharma (USA) LTD. | $33.93 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Anias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.